Trial Profile
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Molibresib (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Aug 2022 Status changed from completed to discontinued.
- 06 Oct 2021 Status changed from active, no longer recruiting to completed.
- 24 Jul 2020 Planned primary completion date changed from 31 Aug 2020 to 31 Jul 2020.